These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

284 related items for PubMed ID: 11897580

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Increased antiviral activity of 1-O-hexadecyloxypropyl-[2-(14)C]cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism.
    Aldern KA, Ciesla SL, Winegarden KL, Hostetler KY.
    Mol Pharmacol; 2003 Mar; 63(3):678-81. PubMed ID: 12606777
    [Abstract] [Full Text] [Related]

  • 6. Comparison of the antiviral activities of alkoxyalkyl and alkyl esters of cidofovir against human and murine cytomegalovirus replication in vitro.
    Wan WB, Beadle JR, Hartline C, Kern ER, Ciesla SL, Valiaeva N, Hostetler KY.
    Antimicrob Agents Chemother; 2005 Feb; 49(2):656-62. PubMed ID: 15673748
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Activities of alkoxyalkyl esters of cidofovir (CDV), cyclic CDV, and (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine against orthopoxviruses in cell monolayers and in organotypic cultures.
    Lebeau I, Andrei G, Dal Pozzo F, Beadle JR, Hostetler KY, De Clercq E, van den Oord J, Snoeck R.
    Antimicrob Agents Chemother; 2006 Jul; 50(7):2525-9. PubMed ID: 16801436
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. In vitro activity of potential anti-poxvirus agents.
    Kern ER.
    Antiviral Res; 2003 Jan; 57(1-2):35-40. PubMed ID: 12615301
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses.
    Smee DF, Sidwell RW, Kefauver D, Bray M, Huggins JW.
    Antimicrob Agents Chemother; 2002 May; 46(5):1329-35. PubMed ID: 11959564
    [Abstract] [Full Text] [Related]

  • 17. Treatment of lethal cowpox virus respiratory infections in mice with 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine and its orally active diacetate ester prodrug.
    Smee DF, Bailey KW, Sidwell RW.
    Antiviral Res; 2002 May; 54(2):113-20. PubMed ID: 12062396
    [Abstract] [Full Text] [Related]

  • 18. Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney.
    Ciesla SL, Trahan J, Wan WB, Beadle JR, Aldern KA, Painter GR, Hostetler KY.
    Antiviral Res; 2003 Aug; 59(3):163-71. PubMed ID: 12927306
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model.
    Buller RM, Owens G, Schriewer J, Melman L, Beadle JR, Hostetler KY.
    Virology; 2004 Jan 20; 318(2):474-81. PubMed ID: 14972516
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.